A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Trial Profile

A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 01 Oct 2017 Results of long-term follow-up data from three phase II studies including this study published in the American Journal of Hematology
    • 10 Jun 2008 Data reported at EHA 2008.
    • 11 Dec 2007 Results reported at ASH 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top